je.st
news
Tag: pharmaceuticals
Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS
2015-03-04 05:59:44| drugdiscoveryonline Home Page
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS)
Tags: development
process
publication
drug
Frost & Sullivan Applauds Neopeutics' Commitment To Accelerating The Delivery Of New Nature-Based Pharmaceuticals And Therapeutics
2015-03-04 05:15:30| drugdiscoveryonline Home Page
Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership
Tags: delivery
commitment
sullivan
frost
Enanta Pharmaceuticals To Present At Barclays Global Healthcare Conference
2015-03-04 04:40:50| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview on March 10, 2015 at 1:35 p.m. ET during the Barclays Global Healthcare Conference in Miami
Tags: present
global
conference
healthcare
Dechra Pharmaceuticals plc Earns "No Rating System"...
2015-03-01 13:45:28| Automakers - Topix.net
's stock had its "no rating system" rating reaffirmed by investment analysts at Edison Investment Research in a note issued to investors on Friday. They currently have a GBX 955 price target on the stock.
Tags: system
rating
plc
pharmaceuticals
Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubists 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertible Senior Notes Due 2020
2015-02-23 23:03:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the Convertible Notes Tender Offer) pursuant to which each holder of Cubists 2.50% Convertible Senior Notes due 2017 (the 2017 Convertible Notes), 1.125% Convertible Senior Notes due 2018 (the 2018 Convertible Notes) and 1.875% Convertible Senior Notes due 2020 (the 2020 Convertible Notes and together with th Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Steve Cragle, (908) 740-1801orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] next »